Profile data is unavailable for this security.
About the company
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function, and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
- Revenue in GBP (TTM)13.61m
- Net income in GBP8.10m
- Incorporated2003
- Employees17.00
- LocationBioventix PLC7 Romans Business Park, East StreetFARNHAM GU9 7SXUnited KingdomGBR
- Phone+44 125 272 8001
- Fax+44 125 272 8002
- Websitehttps://www.bioventix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Futura Medical PLC | 8.40m | -3.75m | 101.06m | 12.00 | -- | 12.86 | -- | 12.03 | -0.0126 | -0.0126 | 0.0272 | 0.0259 | 0.8538 | 5,710.27 | 7.20 | 699,850.80 | -38.14 | -79.25 | -47.43 | -127.22 | 67.70 | -- | -44.68 | -914.37 | 3.75 | -- | 0.00 | -- | -- | -- | -11.40 | -- | 219.68 | -- |
| Scancell Holdings Plc | 0.00 | -5.86m | 139.44m | 61.00 | -- | -- | -- | -- | -0.0068 | -0.0068 | 0.00 | -0.0038 | 0.00 | -- | -- | 0.00 | -23.24 | -31.66 | -32.48 | -37.66 | -- | -- | -- | -822.37 | -- | -- | 1.21 | -- | -100.00 | -- | 50.91 | -- | 131.54 | -- |
| hVIVO PLC | 64.38m | 17.45m | 150.36m | 274.00 | 8.76 | 3.91 | 7.28 | 2.34 | 0.0252 | 0.0252 | 0.0932 | 0.0565 | 0.9242 | -- | 4.25 | 234,974.50 | 25.04 | -0.643 | 46.68 | -1.29 | -- | -- | 27.10 | -0.765 | 1.60 | -- | 0.2530 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.34m | 153.95m | 34.00 | -- | 133.95 | -- | -- | -0.3166 | -0.3166 | 0.00 | 0.011 | 0.00 | -- | -- | 0.00 | -130.90 | -213.06 | -443.92 | -963.12 | -- | -- | -- | -- | -- | -5.99 | 0.9022 | -- | -- | -- | -7.71 | -- | -16.05 | -- |
| Avacta Group Plc | 22.62m | -25.89m | 163.42m | 154.00 | -- | 3.32 | -- | 7.22 | -0.0867 | -0.0867 | 0.075 | 0.1334 | 0.2555 | 4.63 | 3.15 | 146,876.60 | -29.24 | -- | -61.16 | -- | 42.08 | -- | -114.45 | -- | 1.21 | -1.23 | 0.3875 | -- | 140.83 | -- | 32.54 | -- | -- | -- |
| 4Basebio PLC | 596.00k | -9.84m | 166.54m | -- | -- | -- | -- | 279.43 | -0.7843 | -0.7843 | 0.0476 | -0.4075 | 0.0508 | 0.6453 | 10.64 | -- | -83.78 | -- | -97.43 | -- | 69.63 | -- | -1,650.67 | -- | 2.53 | -18.44 | 1.51 | -- | 88.81 | -- | -48.83 | -- | -- | -- |
| Bioventix PLC | 13.61m | 8.10m | 195.74m | 17.00 | 24.53 | 16.31 | 23.84 | 14.39 | 1.53 | 1.53 | 2.57 | 2.30 | 1.01 | 1.57 | 2.26 | 800,387.60 | 59.95 | 58.33 | 67.24 | 63.62 | 93.20 | 93.09 | 59.51 | 64.12 | 7.07 | -- | 0.00 | 90.92 | 6.17 | 7.93 | -3.29 | 6.67 | -28.40 | 16.25 |
| Allergy Therapeutics plc | 55.20m | -40.22m | 262.15m | 635.00 | -- | 70.83 | -- | 4.75 | -0.0107 | -0.0107 | 0.0137 | 0.0008 | 0.8389 | 2.09 | 7.40 | -- | -61.12 | -22.88 | -86.97 | -30.15 | 53.87 | 66.47 | -72.86 | -24.88 | 1.01 | -8.70 | 0.8931 | -- | -7.36 | -5.62 | 6.63 | -- | 1.88 | -- |
| Puretech Health PLC | 369.96k | -65.19m | 388.36m | 90.00 | -- | 1.56 | -- | 1,049.74 | -0.2378 | -0.2378 | 0.0014 | 1.04 | 0.0007 | -- | 0.2252 | 4,110.65 | -14.13 | 4.92 | -16.35 | 5.94 | -- | -- | -19,222.22 | 352.67 | -- | -- | 0.0728 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
| Oxford BioMedica plc | 97.28m | -142.02m | 436.93m | 834.00 | -- | 6.56 | -- | 4.49 | -1.44 | -1.44 | 0.9642 | 0.6292 | 0.3012 | 4.09 | 4.21 | 136,252.10 | -51.98 | -19.60 | -66.85 | -24.68 | 36.74 | 50.74 | -172.59 | -44.38 | 2.07 | -12.47 | 0.6077 | -- | -36.04 | 6.04 | -302.20 | -- | -0.6307 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Liontrust Investment Partners LLPas of 24 Oct 2024 | 574.16k | 11.00% |
| Sanford DeLand Asset Management Ltd.as of 24 Oct 2024 | 568.94k | 10.90% |
| Link Fund Solutions Ltd.as of 31 May 2024 | 363.63k | 6.97% |
| Gresham House Asset Management Ltd. (Investment Management)as of 01 Jun 2024 | 363.00k | 6.95% |
| Rathbones Investment Management Ltd.as of 24 Oct 2024 | 323.62k | 6.20% |
| Schroder Investment Management Ltd.as of 24 Oct 2024 | 287.08k | 5.50% |
| Investec Wealth & Investment Ltd.as of 01 Jun 2024 | 243.00k | 4.66% |
| Santander Asset Management UK Ltd.as of 01 Jun 2024 | 207.00k | 3.97% |
| Danske Bank A/S (Investment Management)as of 31 Oct 2024 | 185.66k | 3.56% |
| Hargreaves Lansdown Asset Management Ltd.as of 01 Jun 2024 | 99.00k | 1.90% |
